KAPOSI'S SYNDROME HERPESVIRUS PROTEASE AND ASSEMBLY PROTEIN

While relatively uncommon in HIV-negative individuals, Kaposi's sarcoma associated herpesvirus (KSHV) is known to cause tumors in approximately one third of patients with acquired immunodeficiency syndrome (AIDS). In addition to being especially common among HIV-positive individuals, Kaposi's sarcoma (KS)is also more aggressive. Recent success of HIV chemotherapeutic intervention with protease inhibitors suggests a similar strategy may be effective for anti-KS therapeutics. Defining the protease target of KSHV is an essential step in achieving this goal.

Researchers at UCSF have identified the KSHV protease and assembly protein. Additionally, they have purified and characterized the KSHV protease. This discovery should allow for diagnosing and determining patient status with respect to KSHV as well as for development of drug candidates capable of inhibiting the KSHV protease.

If you would like to receive further information about this technology and potential licensing opportunities, please contact:

Joel B. Kirschbaum, Ph.D.
Director & Senior Technology Portfolio Manager
(415) 353-4462 phone
(415) 348-1579 fax
Joel Kirschbaum, Ph.D.

Reference: OTM Case #SF97-022